Penumbra Inc (PEN)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $12.65B
Last updated: Nov 17, 2026 at 11:05 AM ET
Penumbra Inc (PEN) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Penumbra reported EPS of $1.07, below the $1.21 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 22.0% above the $1.18 reported for the quarter ended Dec 31, 2025.
PEN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
PEN Earnings Call
The latest PEN earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, PEN beat 29, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $410.14M, up 15.6% from $354.69M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.07 | $1.21 | $1.07 - $1.29 | -11.57% | Miss | +10.3% | 7 | 1 up, 3 down | Oct 29, 2026 | $410.14M |
| Jun 30, 2026 | $0.88 | $1.15 | $1.05 - $1.27 | -23.48% | Miss | +2.3% | 11 | 0 up, 5 down | Jul 30, 2026 | $390.05M |
| Mar 31, 2026 | $1.01 | $1.06 | $1.00 - $1.14 | -4.72% | Miss | +21.7% | 10 | 2 up, 2 down | May 6, 2026 | $374.76M |
| Dec 31, 2025 | $1.18 | $1.10 | $0.99 - $1.24 | +7.27% | Beat | +21.6% | 18 | 4 up, 1 down | Feb 25, 2026 | $385.38M |
| Sep 30, 2025 | $0.97 | $0.90 | $0.85 - $1.03 | +7.78% | Beat | +14.1% | 19 | 3 up, 14 down | Nov 5, 2025 | $354.69M |
| Jun 30, 2025 | $0.86 | $0.82 | $0.71 - $0.90 | +4.88% | Beat | +34.4% | 18 | 0 up, 1 down | Jul 29, 2025 | $339.45M |
| Mar 31, 2025 | $0.83 | $0.67 | $0.52 - $0.84 | +23.88% | Beat | +102.4% | 18 | 2 up, 2 down | Apr 23, 2025 | $324.14M |
| Dec 31, 2024 | $0.97 | $0.89 | $0.80 - $1.08 | +8.54% | Beat | +27.6% | 18 | 2 up, 1 down | Feb 18, 2025 | $315.52M |
| Sep 30, 2024 | $0.85 | $0.69 | $0.50 - $0.85 | +23.19% | Beat | +26.9% | 17 | 1 up, 0 down | Oct 30, 2024 | $301.04M |
| Jun 30, 2024 | $0.64 | $0.56 | $0.51 - $0.61 | +14.29% | Beat | +48.8% | 15 | 0 up, 0 down | Jul 30, 2024 | $299.40M |
| Mar 31, 2024 | $0.41 | $0.38 | $0.30 - $0.61 | +7.89% | Beat | +78.3% | 14 | 0 up, 0 down | May 7, 2024 | $278.65M |
| Dec 31, 2023 | $0.76 | $0.70 | $0.57 - $0.87 | +8.57% | Beat | +375.0% | 14 | 1 up, 0 down | Feb 22, 2024 | $284.68M |
| Sep 30, 2023 | $0.67 | $0.45 | $0.40 - $0.53 | +48.89% | Beat | +6600.0% | 14 | 0 up, 0 down | Nov 2, 2023 | $270.95M |
| Jun 30, 2023 | $0.43 | $0.28 | $0.17 - $0.34 | +53.57% | Beat | +4200.0% | 13 | 0 up, 0 down | Aug 1, 2023 | $261.50M |
| Mar 31, 2023 | $0.23 | $0.11 | $0.04 - $0.17 | +109.09% | Beat | N/A | 12 | 0 up, 0 down | May 2, 2023 | $241.40M |
| Dec 31, 2022 | $0.16 | $0.15 | $0.07 - $0.23 | +6.67% | Beat | +60.0% | 12 | 0 up, 0 down | Feb 23, 2023 | $221.22M |
| Sep 30, 2022 | $0.01 | $0.01 | -$0.11 - $0.07 | 0.00% | In line | -91.7% | 11 | 0 up, 0 down | Nov 3, 2022 | $213.68M |
| Jun 30, 2022 | $0.01 | -$0.03 | -$0.17 - $0.05 | +133.33% | Beat | -95.2% | 10 | 1 up, 0 down | Aug 4, 2022 | $208.34M |
| Mar 31, 2022 | -$0.01 | $0.04 | -$0.05 - $0.21 | -125.00% | Miss | -103.7% | 9 | 0 up, 0 down | May 3, 2022 | $203.90M |
| Dec 31, 2021 | $0.10 | $0.22 | $0.12 - $0.33 | -54.55% | Miss | -76.2% | 7 | 0 up, 0 down | Feb 22, 2022 | $204.01M |
| Sep 30, 2021 | $0.12 | $0.17 | $0.06 - $0.23 | -29.41% | Miss | +100.0% | 8 | N/A | Nov 3, 2021 | $190.12M |
| Jun 30, 2021 | $0.21 | $0.17 | $0.09 - $0.24 | +23.53% | Beat | N/A | 7 | N/A | Aug 9, 2021 | $184.26M |
| Mar 31, 2021 | $0.27 | $0.09 | -$0.04 - $0.21 | +200.00% | Beat | +575.0% | 7 | N/A | May 4, 2021 | $169.20M |
| Dec 31, 2020 | $0.42 | -$0.07 | -$0.38 - $0.18 | +700.00% | Beat | +90.9% | 7 | N/A | Feb 23, 2021 | $166.90M |
| Sep 30, 2020 | $0.06 | -$0.08 | -$0.14 - $0.00 | +175.00% | Beat | -76.0% | 7 | N/A | Oct 28, 2020 | $151.08M |
| Jun 30, 2020 | -$0.30 | -$0.39 | -$0.57 - -$0.18 | +23.08% | Beat | -211.1% | 6 | N/A | Aug 3, 2020 | $105.11M |
| Mar 31, 2020 | $0.04 | $0.13 | $0.00 - $0.23 | -69.23% | Miss | -82.6% | 6 | N/A | May 7, 2020 | $137.33M |
| Dec 31, 2019 | $0.22 | $0.19 | $0.13 - $0.23 | +15.79% | Beat | +69.2% | 5 | N/A | Feb 25, 2020 | $145.26M |
| Sep 30, 2019 | $0.25 | $0.16 | $0.12 - $0.21 | +56.25% | Beat | +47.1% | 6 | N/A | Nov 7, 2019 | $139.50M |
| Jun 30, 2019 | $0.27 | $0.22 | $0.19 - $0.25 | +22.73% | Beat | +80.0% | 7 | N/A | Aug 6, 2019 | $134.20M |
| Mar 31, 2019 | $0.23 | $0.11 | $0.05 - $0.22 | +109.09% | Beat | +283.3% | 6 | N/A | May 7, 2019 | $128.44M |
| Dec 31, 2018 | $0.13 | $0.12 | $0.04 - $0.20 | +8.33% | Beat | -80.9% | 7 | N/A | Feb 26, 2019 | $120.79M |
| Sep 30, 2018 | $0.17 | $0.04 | -$0.04 - $0.09 | +325.00% | Beat | +1600.0% | 5 | N/A | Nov 5, 2018 | $111.81M |
| Jun 30, 2018 | $0.15 | $0.03 | $0.02 - $0.03 | +400.00% | Beat | N/A | 5 | N/A | Aug 7, 2018 | $109.64M |
| Mar 31, 2018 | $0.06 | -$0.02 | -$0.05 - $0.02 | +400.00% | Beat | N/A | 7 | N/A | May 8, 2018 | $102.70M |
| Dec 31, 2017 | $0.68 | -$0.01 | -$0.04 - $0.01 | N/A | N/A | N/A | 6 | N/A | Feb 27, 2018 | $96.05M |
| Sep 30, 2017 | $0.01 | -$0.05 | -$0.10 - -$0.01 | +120.00% | Beat | N/A | 5 | N/A | Nov 7, 2017 | $83.91M |
| Jun 30, 2017 | -$0.05 | -$0.03 | -$0.07 - $0.03 | -66.67% | Miss | -600.0% | 5 | N/A | Aug 8, 2017 | $80.59M |
| Mar 31, 2017 | -$0.10 | -$0.05 | N/A | -100.00% | Miss | -600.0% | N/A | N/A | May 9, 2017 | $73.21M |
| Dec 31, 2016 | -$0.08 | -$0.09 | N/A | +11.11% | Beat | -260.0% | N/A | N/A | Feb 28, 2017 | $73.11M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.84, up 33.8% from the year before. It was -$0.09 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.84 | +33.8% |
| Dec 31, 2024 | $2.87 | +37.3% |
| Dec 31, 2023 | $2.09 | +1129.4% |
| Dec 31, 2022 | $0.17 | -75.7% |
| Dec 31, 2021 | $0.70 | +218.2% |
| Dec 31, 2020 | $0.22 | -77.3% |
| Dec 31, 2019 | $0.97 | +90.2% |
| Dec 31, 2018 | $0.51 | N/A |
| Dec 31, 2017 | $0.54 | N/A |
| Dec 31, 2016 | -$0.09 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 7,100 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 7,093 | 15 | |
| 2025Q2 | Jun 30, 2025 | 7,878 | 17 | |
| 2025Q1 | Mar 31, 2025 | 8,598 | 16 | |
| 2024Q4 | Dec 31, 2024 | 7,627 | 17 | |
| 2024Q3 | Sep 30, 2024 | 6,041 | 12 | |
| 2024Q2 | Jun 30, 2024 | 7,984 | 9 |
2025Q3 Earnings Call
Opening remarks
Cecilia Furlong Business Development and Investor Relations Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for the third quarter of 2025. A copy of the press release and financial tables, which includes a GAAP to non-GAAP reconciliation, can be viewed under the Investors tab on our company website at www.penumbrainc.com. With me on today's call are Adam Elsesser, Chairman and CEO; Shruthi Narayan, President; and Maggie Yuen, Chief Financial Officer. Also joining us for the Q&A portion of the call is Jason Mills, EVP, Strategy. During the course of this conference call, the company will make forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial performance, commercialization, clinical trials, regulatory status, quality, compliance and business trends. Actual results could differ materially from those stated or implied by our forward-looking statements due to certain risks and uncertainties, including those referenced in our 10-K for the year ended December 31, 2024, filed with the SEC. As a result, we caution you against placing undue reliance on these forward-looking statements, and we encourage you to review our periodic filings with the SEC, including the 10-K previously mentioned, for a more complete discussion of these factors and other risks that may affect our future results or the market price of our stock. Penumbra disclaims any duty to update or revise our forward-looking statements as a result of new information, future events, developments or otherwise. On this call, financial results for revenue and gross margin are presented on a GAAP basis, while operating expenses, operating income, and adjusted EBITDA are presented on a non-GAAP basis. The corresponding GAAP measures and a reconciliation of GAAP to non-GAAP financial measures are provided in our posted press release. Non-GAAP operating expenses and operating income exclude expenses related to the wind down of our Immersive Healthcare business in the third quarter of 2024 of $5 million and adjusted EBITDA excludes wind-down expenses, stock compensation expense, depreciation and amortization, provision for income taxes and interest income expenses. And with that, I would like to turn the call over to Adam.
Adam Elsesser Chairman and CEO Thank you, Cecilia. Good afternoon. Thank you for joining Penumbra's Third Quarter 2025 Conference Call. In the third quarter, we generated total revenue of $354.7 million, representing underlying year-over-year growth of 17.8% on a reported basis and 16.9% on a constant currency basis. Our strong third quarter results reflect broad-based execution against our strategy and significant progress in further enhancing our competitive technological and market positioning across all franchises. Total U.S. revenue was $275 million in the third quarter, an increase of 21.5% compared to the third quarter of 2024. Total U.S.
Frequently Asked Questions About PEN
Did PEN beat earnings estimates last quarter?
No. Penumbra reported EPS of $1.07 for the quarter ended Sep 30, 2026, below the $1.21 estimate by 11.57%.
What EPS do analysts expect from PEN next quarter?
The consensus EPS estimate for Penumbra for the quarter ending Dec 31, 2026 is $1.44 from 11 analysts, with estimates from $1.10 to $1.69.
How often does PEN beat earnings estimates?
Penumbra beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.57%.
PEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts